Inlexo Kit, methotrexate autoinjector

About Inlexo Kit

Inlexo Kit (methotrexate prefilled pen) is manufactured by Medac GmbH and distributed in the United States through STADA. It is a subcutaneous methotrexate autoinjector indicated for active rheumatoid arthritis (RA) in adults, polyarticular juvenile idiopathic arthritis (JIA) in patients aged 2 and older, and moderate-to-severe plaque psoriasis in adults inadequately controlled on conventional therapies. Methotrexate is a folate antagonist (dihydrofolate reductase inhibitor) with disease-modifying activity in autoimmune disease. International patients may access Inlexo Kit through Named Patient Program or personal-import pathways.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

How Reserve Meds coordinates Inlexo Kit

1. Patient or treating physician submits a named-patient request.
2. Clinical team verifies appropriateness of Inlexo Kit for the patient and destination country.
3. Treating physician issues prescription and clinical justification.
4. Country-specific NPP / personal-import documentation is prepared.
5. Inlexo Kit is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
6. Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).

Access by country

Reserve Meds publishes a detailed country deep-dive for Inlexo Kit in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.

Start a request for Inlexo Kit

Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.

Request Inlexo Kit